Entrada Therapeutics, Inc. (TRDA) Research

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

Market snapshot

Symbol
TRDA
Price
$7.09
Day change
+4.11%
Market cap
$275.2M
P/E ratio
-1.79x
52-week range
4.93-16.45
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$16.00

Recent news

  • Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

    Entrada Therapeutics, Inc. (NASDAQ:TRDA) stock is trading lower on Thursday as the stock reacts to news regarding its clinical trial data in Duchenne muscular dystrophy patients.

  • Entrada's Duchenne drug shown to improve muscle function in early trial

    Entrada Therapeutics said on Thursday its drug improved a key measure of muscle function in children with Duchenne muscular dystrophy, ​a rare and fatal muscle-wasting disease, in an early-to-mid ‌stage trial.

Peer companies

  • Achieve Life Sciences, Inc. (ACHV)
  • Allogene Therapeutics, Inc. (ALLO)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Atea Pharmaceuticals, Inc. (AVIR)
  • Capricor Therapeutics, Inc. (CAPR)
  • Humacyte, Inc. (HUMA)
  • Immuneering Corporation (IMRX)
  • Sagimet Biosciences Inc. (SGMT)

Recent insider activity

  • PARMAR KUSH — A-Award (19000 shares) on 2026-06-10
  • KIM PETER S — A-Award (19000 shares) on 2026-06-10
  • Chapman Gina — A-Award (19000 shares) on 2026-06-10
  • Radhakrishnan Maha — A-Award (19000 shares) on 2026-06-10
  • Thistle Mary — A-Award (19000 shares) on 2026-06-10

Open Entrada Therapeutics, Inc. (TRDA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.